Cobitolimod
- Generic Name
- Cobitolimod
- Drug Type
- Biotech
- CAS Number
- 1226822-98-5
- Unique Ingredient Identifier
- 328101264R
- Background
Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT05404074
- Locations
- 🇸🇪
CTC, Clinical Trial Consultants AB, Uppsala, Sweden
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Phase 3
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT04985968
- Locations
- ðŸ‡ðŸ‡·
Opca bolnica Bjelovar, Bjelovar, Croatia
ðŸ‡ðŸ‡·University Hospital Centre Zagreb, Zagreb, Croatia
ðŸ‡ðŸ‡·Clinical Hospital Osijek, Osijek, Croatia
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 213
- Registration Number
- NCT03178669
- Locations
- 🇷🇺
34, Cheboksary, Russian Federation
🇺🇦53, Dnipropetrovs'k, Ukraine
🇺🇦56, Kiev, Ukraine
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- InDex Pharmaceuticals
- Target Recruit Count
- 131
- Registration Number
- NCT01493960
- Locations
- 🇵🇱
Site 604, Krakow, Poland
🇬🇧Site 101, Nottingham, United Kingdom
🇨🇿Site 406, Ostrava, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath